Enterprise AI Analysis
Modified ShuffleNet trained on gradient pattern and shape-based features for lung cancer classification with improved M-SegNet segmentation
Lung cancer (LC) is one of the leading causes of death globally. Early detection is essential for saving lives and ensuring effective treatment for patients. When medical professionals can proactively diagnose and classify the condition, they can provide safer and more targeted interventions. The development of automated tools for early detection is vital to identify malignant states at their beginning. Despite the numerous algorithms used by researchers over the years, achieving high prediction accuracy remains a significant challenge. Considering this challenge, a novel Deep Learning (DL) model is proposed for lung cancer classification. The proposed method utilizes a novel Custom Mean Normalisation-based ShuffleNet (CMN-ShuffleNet) model designed for lung cancer classification. The method is divided into four key phases, including preprocessing, lobe segmentation, feature extraction, and classification. Initially, the input lung images undergo Histogram Equalization (HE) in the preprocessing step. Following this, the Modified Residual Recurrent based SegNet (mRRB-SegNet) model is employed for lobe segmentation. This modification improves the model's capabilities and accuracy. From the segmented images, various features are extracted, which include Improved Local Gradient Pattern (ILGP), shape and statistical features. The final phase includes the CMN-ShuffleNet model to classify the lung cancer based on the extracted features. The effectiveness of the CMN-ShuffleNet model is confirmed via extensive statistical analysis that proves its superior performance in lung cancer classification with significant enhancements in metrics like accuracy, F1-score, precision, and recall compared to conventional techniques. For lung cancer classification LUNA16 dataset was used. The CMN-ShuffleNet approach has the highest accuracy rate of 95.8%. The CMN-ShuffleNet method achieved a sensitivity of 0.957 with 90% training data, indicating that it is a successful method for classifying lung cancer. The mRRB-SegNet attained the highest dice score of 0.926.
Key Performance Indicators
Our analysis reveals the transformative potential of this AI model for precision diagnostics.
Deep Analysis & Enterprise Applications
Select a topic to dive deeper, then explore the specific findings from the research, rebuilt as interactive, enterprise-focused modules.
Enterprise Process Flow
| Feature | CMN-ShuffleNet Key Advantages |
|---|---|
| Performance |
|
| Segmentation |
|
| Feature Extraction |
|
| Efficiency |
|
Real-world Impact & Clinical Integration
The Modified ShuffleNet model, with its enhanced M-SegNet segmentation and gradient/shape-based features, offers significant real-world applications in medical imaging and diagnostics. It assists radiologists in accurately identifying and categorizing lung nodules in CT scans, facilitating earlier and more precise diagnoses. Its lightweight design enables real-time analysis on low-power devices, making it suitable for point-of-care diagnostics, telemedicine, and rural healthcare. The model's precise segmentation and feature integration improve clinical outcomes and support personalized patient care, surgical planning, and treatment monitoring.
Faster, More Accurate Lung Cancer Diagnosis in Clinical Settings.
Calculate Your Potential ROI
Estimate the efficiency gains and cost savings for your enterprise with AI-powered diagnostic solutions.
AI Implementation Roadmap
A phased approach to integrate AI for maximum impact and minimal disruption.
Phase 1: Assessment & Strategy (2-4 Weeks)
Conduct a detailed analysis of existing diagnostic workflows, data infrastructure, and identify key integration points for the CMN-ShuffleNet model. Define success metrics and a clear implementation roadmap tailored to your organizational needs.
Phase 2: Data Preparation & Model Customization (4-8 Weeks)
Prepare and normalize your CT imaging datasets, ensuring compatibility with the mRRB-SegNet and CMN-ShuffleNet architectures. Custom-tune the model parameters and attention mechanisms for optimal performance on your specific patient population and data characteristics.
Phase 3: Integration & Pilot Deployment (6-12 Weeks)
Seamlessly integrate the AI solution with your existing PACS or EHR systems. Conduct a pilot program in a controlled clinical environment, gathering feedback and fine-tuning the system for accuracy and user experience. Validate results against human expert diagnoses.
Phase 4: Full-Scale Rollout & Continuous Optimization (Ongoing)
Deploy the CMN-ShuffleNet model across your enterprise, providing comprehensive training to clinical staff. Establish continuous monitoring, performance tracking, and iterative updates to ensure long-term efficacy and adapt to evolving clinical guidelines and data. Leverage AI for ongoing research and insights.
Ready to Transform Your Diagnostics?
Connect with our AI specialists to discuss how CMN-ShuffleNet can enhance your precision medicine initiatives and drive significant operational efficiencies.